Yang S, Li M, Lian G, Wu Y, Cui J, Wang L
Gutman cautioned that investors should not assume pet GLP-1s will mirror the explosive commercial success of human obesity drugs
Lower Cholesterol & Blood Pressure Patients who lost weight using GLP-1 medications also experienced significant drops in LDL cholesterol and blood pressure, both key risk factors for heart disease
That might mean staying on GLP-1s long-term or transitioning to another medication strategy
This weekly dosing schedule is consistent with other agents in the incretin-based injectable class, such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro), and is designed to maintain stable plasma drug concentrations throughout the week whilst minimising the burden of frequent injections
A new assay procedure for the enzymes and studies on their intracellular localization